The Effect of Bevacizumab (Avastin) on Pterygium
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effect of Bevacizumab (Avastin) on Pterygium|
- The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
Growth of the pterygium was defined as an increase in the area of the pterygium as measured from the limbus toward the visual axis. This would be a positive change value indicating progression
Regression of the pterygium was defined as a decrease in the area of the pterygium length measured from the limbus toward the visual axis. This would be negative change value indicating regression.
- Number of Patients Having Surgical Removal of Pterygium. [ Time Frame: 12 months ] [ Designated as safety issue: No ]The number of patients having surgical removal of pterygium within 12 months.
|Study Start Date:||August 2007|
|Study Completion Date:||March 2010|
|Primary Completion Date:||March 2010 (Final data collection date for primary outcome measure)|
Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
Drug: local injection of bevacizumab
Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00592176
|United States, Alabama|
|Callahan Eye Foundation Hospital|
|Birmingham, Alabama, United States, 35233|
|Principal Investigator:||Tyler A Hall, MD||University of Alabama at Birmingham|